glp 1 drugs and fatty liver GLP-1 MASH Approval: What Patients Should Know Glucagon‐like peptide‐1 receptor agonists (GLP‐1
Description
Novo Nordisk is also looking to extend the indications for semaglutide even further, with trials on the go in metabolic dysfunction-associated steatohepatitis (MASH) and Alzheimer's disease.
About half think the medication should be affordable and covered by insurance
Interestingly, the combination of GLP-1 and GIP on glucagon secretion is reported either to offset 31,32,33 or to decrease glucagon levels 34
In vitro , liraglutide dose-dependently downregulates pro-inflammatory mediators such as Mcp-1 and Cd38 in LPS-activated RAW264.7 macrophages, while simultaneously upregulating Erg-2, an M2-specific transcription factor (Yu et al., 2019)
A recent article revealed that while Ozempic costs $936 a month for Americans, those in the UK pay just $93
Cover Story The GLP-1 drug shortage is over
